PF-Atlas › Clinical Trials › NCT03619616

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults

ZSP1603 7.5 mg · Phase 1

Registry ID
NCT03619616
Phase
Phase 1
Status
Completed
Drug / intervention
ZSP1603 7.5 mg
Sponsor
Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Start
2018-07-16
Enrollment
40
Locations
1

About this trial

The Primary objectives of this study are to evaluate the safety and tolerability of ZSP1603 and the Secondary objective is to estimate the pharmacokinetic (PK) parameters after orally administered once daily of ZSP1603.

View NCT03619616 on ClinicalTrials.gov →

Explore related

All ZSP1603 7.5 mg trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT03619616 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.